CMS Reviews Medicare Coverage With Evidence Development May 9
This article was originally published in The Pink Sheet Daily
Executive Summary
Open door forum will consider factors in providing Coverage with Evidence Development. Part B drugs are eligible for CED; comment deadline on CED draft guidance is June 6.